Evidence mapPaperPMID 33627633Full record

Trial reportNutrition & diabetes2021

Metabolites and diabetes remission after weight loss.

Lydia Coulter Kwee, Olga Ilkayeva, Michael J Muehlbauer, Nathan Bihlmeyer, Bruce Wolfe, Jonathan Q Purnell, F Xavier Pi-Sunyer, Haiying Chen, Judy Bahnson, Christopher B Newgard and 2 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrition & diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Lydia Coulter KweeDuke Molecular Physiology Institute, Durham, NC, USA.ORCID 0000-0002-6997-8571
Olga IlkayevaDuke Molecular Physiology Institute, Durham, NC, USA.
Michael J MuehlbauerDuke Molecular Physiology Institute, Durham, NC, USA.
Nathan BihlmeyerDuke Molecular Physiology Institute, Durham, NC, USA.
Bruce WolfeDepartments of Surgery and Medicine, Oregon Health & Science University,, Portland, OR, USA.
Jonathan Q PurnellDepartments of Surgery and Medicine, Oregon Health & Science University,, Portland, OR, USA.
F Xavier Pi-SunyerNew York Obesity Research Center, Division of Endocrinology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Haiying ChenDepartment of Biostatistics and Data Science, Wake Forest School of Medicine Medical Center, Winston-Salem, NC, USA.
Judy BahnsonDepartment of Biostatistics and Data Science, Wake Forest School of Medicine Medical Center, Winston-Salem, NC, USA.
Christopher B NewgardDuke Molecular Physiology Institute, Durham, NC, USA.
Svati H Shah *Duke Molecular Physiology Institute, Durham, NC, USA.
Blandine Laferrère *New York Obesity Research Center, Division of Endocrinology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. BBL14@columbia.edu.ORCID 0000-0001-8255-3175
Duke Medical Center · USColumbia University · USOregon Health & Science University · USWake Forest University · USDuke University · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$37.2M
ZIPRASIDONE IN NORMAL HEPATIC FUNCTION SUBJECTS &IN HEPATIC DYSFUCTIN SUBJECTSM01RR000037 · UNIVERSITY OF WASHINGTON · 1985 to 2005
$28.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1985 to 2005
$27.6M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
HEALTH OUTCOMES OF WEIGHT-LOSS: DATA COORDINATING CENTERU01DK057136 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$18.5M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · JOHNS HOPKINS UNIVERSITY · 1986 to 2005
$16.4M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · 1985 to 2005
$16.1M
Clinical and Translational Science CenterUL1TR002384 · WEILL MEDICAL COLL OF CORNELL UNIV · 2025 to 2025
$9.8M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057178 · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · 1999 to 2005
$9.3M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057151 · UNIVERSITY OF COLORADO DENVER · 1999 to 2005
$8.4M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057135 · UNIVERSITY OF PENNSYLVANIA · 1999 to 2005
$8.2M
SHOW PROJECTU01DK057154 · MASSACHUSETTS GENERAL HOSPITAL · 1999 to 2005
$8.1M
NCRR NIH HHS M01 RR000037NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01 RR002719NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR024996NCRR NIH HHS UL1 RR025758NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS R01 DK108580NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219NIDDK NIH HHS U01 DK066471NIDDK NIH HHS U01 DK066526NIDDK NIH HHS U01 DK066555NIDDK NIH HHS U01 DK066557NIDDK NIH HHS U01 DK066568NIDDK NIH HHS U01 DK066585NIDDK NIH HHS U01 DK066667U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) 5U01DK057136U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) 5U01DK057178U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) NIH R01 DK108580
6 · The paper itself

Abstract

There is marked heterogeneity in the response to weight loss interventions with regards to weight loss amount and metabolic improvement. We sought to identify biomarkers predictive of type 2 diabetes remission and amount of weight loss in individuals with severe obesity enrolled in the Longitudinal Assessment of Bariatric Surgery (LABS) and the Look AHEAD (Action for Health in Diabetes) studies. Targeted mass spectrometry-based profiling of 135 metabolites was performed in pre-intervention blood samples using a nested design for diabetes remission over five years (n = 93 LABS, n = 80 Look AHEAD; n = 87 remitters), and for extremes of weight loss at five years (n = 151 LABS; n = 75 with high weight loss). Principal components analysis (PCA) was used for dimensionality reduction, with PCA-derived metabolite factors tested for association with both diabetes remission and weight loss. Metabolic markers were tested for incremental improvement to clinical models, including the DiaRem score. Two metabolite factors were associated with diabetes remission: one primarily composed of branched chain amino acids (BCAA) and tyrosine (odds ratio (95% confidence interval) [OR (95% CI)] = 1.4 [1.0-1.9], p = 0.045), and one with betaine and choline (OR [95% CI] = 0.7 [0.5-0.9], p = 0.02).These results were not significant after adjustment for multiple tests. Inclusion of these two factors in clinical models yielded modest improvements in model fit and performance: in a constructed clinical model, the C-statistic improved from 0.87 to 0.90 (p = 0.02), while the net reclassification index showed improvement in prediction compared to the DiaRem score (NRI = 0.26, p = 0.0013). No metabolite factors associated with weight loss at five years. Baseline levels of metabolites in the BCAA and trimethylamine-N-oxide (TMAO)-microbiome-related pathways are independently and incrementally associated with sustained diabetes remission after weight loss interventions in individuals with severe obesity. These metabolites could serve as clinically useful biomarkers to identify individuals who will benefit the most from weight loss interventions.

Indexed as

Weight LossAmino Acids, Branched-ChainBariatric SurgeryBetaineBiomarkersCholineDiabetes Mellitus, Type 2FemaleHumansMaleMass SpectrometryMethylaminesMiddle AgedObesityObesity, MorbidRemission InductionAmino Acids, Branched-ChainBetaineBiomarkersCholineMethylaminestrimethyloxamineTyrosine

Identifiers

PMID33627633
PMCPMC7904757
OpenAlexW3130441215

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.